Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rifabutin · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Azithromycin | DRUG | - |
| Rifabutin | DRUG | - |
| Fluconazole | DRUG | - |
Inclusion Criteria Concurrent Medication: Allowed: * Preventive therapy with isoniazid for M. tuberculosis. * Maintenance therapy for CMV retinitis. Patients must have: * HIV infection or history of an AIDS-defining condition by CDC criteria. * One documented CD4 count \< 100 cells/mm3 within 1...
Rifabutin is an investigational small molecule being studied for the prevention of disseminated Mycobacterium avium complex (MAC) and fungal infections in HIV-infected patients. It is in Phase 3 clinical development for mycoses, a type of fungal infection, within the infectious disease therapeutic area.
Rifabutin is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 3 clinical development for the prevention of certain infections in HIV-infected patients.
Rifabutin is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy for preventing disseminated Mycobacterium avium complex and fungal infections in HIV-infected patients.
Rifabutin has one completed Phase 3 clinical trial, identified by the National Clinical Trial number NCT00002122. This study evaluated daily and intermittent prophylactic regimens for the prevention of disseminated Mycobacterium avium complex and fungal infections in HIV-infected patients. The trial enrolled 720 participants in the United States.
Rifabutin is a distinct drug entity and is not known by any alternative names. It is a small molecule being developed by Pfizer, Inc. for the prevention of certain infections in HIV-infected patients, and it is currently in Phase 3 clinical development.